"Clinically, this model could help target intensive preventive therapies, such as SGLT2 inhibitors, to patients most likely to benefit," Dr. Pandey said, referring to a class of medications used ...

As Fady will elaborate, the additional analyses show that treatment with aficamten is associated with improvements in exercise capacity, gradients, symptoms, biomarkers, cardiac structure and ...

Of note, a similar proportion of patients in the empagliflozin and placebo groups (43% and 40%, respectively) were using an SGLT2 inhibitor during the post-trial period, they wrote in the New ...

Use vs non-use of sodium-glucose cotransporter 2 inhibitors by older patients with CKD stages 4-5D is significantly associated with reductions in all-cause mortality risk at 6, 12, and 60 months.

Q3 2024 Earnings Conference Call November 6, 2024 8:30 AM ETCompany ParticipantsBill Szablewski - Head of Capital ...

Sodium-glucose co-transporter 2 (SGLT2) inhibitors reduce the risk of cardiovascular and kidney outcomes in patients with ...

Objective Sodium–glucose cotransporter 2 (SGLT-2) inhibitors are the most recently approved antihyperglycemic medications. We sought to describe their association with euglycemic diabetic ...

New phase 3b trial results show Lilly’s Trulicity has helped type 2 diabetes patients already taking an SGLT2 inhibitor but whose blood sugar was inadequately controlled. The AWARD trial showed ...

Drugs for diabetic kidney disease treatment have greatly expanded, allowing research and consensus on their optimal use.